Prof. John Overington, the CIO of the Medicines Discovery Catapult describes the AssayNet project and its very far reaching implications.

Creating novel drugs is an extraordinarily hard and complex problem.

One of the many challenges in drug design is the sheer size of the search space for novel chemical compounds. Scientists need to find molecules that are active toward a biological target or pathway and at the same time have acceptable ADMET properties.

There is now considerable research going on using various AI and ML approaches to tackle these challenges.

Our distinguished speakers, Drs. Alex Tropsha and Ola Engkvist, will discuss their recent work in Drug Design involving Deep Reinforcement Learning and Neural Networks, and will answer questions from the audience on the current state of the research in the field.

Data Quality is at the heart of AI/ML and is one of the key challenges we face in Life Sciences to make AI a success.

In this panel we discuss how to address these data quality issues and what steps we need to take to improve things in the future. We will also look at practical ways to improve things now.